Becton, Dickinson(US:BDX) Prnewswire·2025-11-06 11:30Core Insights - BD reported a resilient business model with a 3.9% organic growth in fiscal 2025, alongside significant adjusted margin and earnings growth [2] - The company is on track to complete the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation by the end of Q1 2026, aiming to enhance its position in the Med Tech industry [2] Financial Performance - Q4 2025 revenues reached $5.89 billion, marking an 8.3% increase year-over-year, with a 3.9% organic growth [4][6] - For FY 2025, total revenues were $21.84 billion, up 8.2% from FY 2024, with adjusted diluted EPS growing by 9.6% to $14.40 [6][27] - Q4 GAAP diluted EPS increased to $1.72, a 24.6% rise compared to the previous year [6][27] Segment Performance - BD Medical segment revenues grew by 11.2% to $3.16 billion, driven by strong performance in Advanced Patient Monitoring [9][32] - BD Life Sciences segment saw a modest growth of 2.1% to $1.37 billion, with Specimen Management showing solid performance [11][32] - BD Interventional segment revenues increased by 8.5% to $1.37 billion, with notable growth in Urology and Critical Care [12][32] Geographic Results - In the United States, revenues increased by 9.8% to $3.42 billion, while international revenues grew by 6.4% to $2.47 billion [5][32] - The U.S. market showed strong growth across various segments, particularly in Medication Delivery Solutions and Advanced Patient Monitoring [30][31] Future Outlook - The company provided guidance for FY 2026, expecting low single-digit revenue growth and adjusted diluted EPS in the range of $14.75 to $15.05 [13][14] - The outlook reflects various assumptions about market conditions and operational performance [13]